Complement activation-related pseudoallergy: A stress reaction in blood triggered by nanomedicines and biologicals

Molecular Immunology

Volumn 61, Issue 2, 2014, Pages 163-173

  Szebeni, Janos ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Allergy; Anaphylatoxins; Anaphylaxis; CARPA; Inflammatory mediators; Pseudoallergy

Indexed keywords

ACETRIZOIC ACID; ADIPIODONE; AMPHOTERICIN B LIPID COMPLEX; ANTIHISTAMINIC AGENT; CARBON NANOTUBE; CORTICOSTEROID; CREMOPHOR; DIATRIZOATE; DOCETAXEL; DOXORUBICIN; INTRALIPID; IOHEXOL; IOPANOIC ACID; IOPROMIDE; IOTALAMIC ACID; LIPOSOME; MACROGOL; MEGLUMINE DIATRIZOATE PLUS SODIUM DIATRIZOATE; METRIZAMIDE; OMNIPAC; PACLITAXEL; RITUXIMAB; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ALLERGY; APNEA; BACK; BLOATING; BRONCHOSPASM; CARDIOGENIC SHOCK; CHEST TIGHTNESS; CHILL; COMPLEMENT ACTIVATION; CONFUSION; COUGHING; CYANOSIS; DIAPHORESIS; DIARRHEA; DIZZINESS; DYSPNEA; EDEMA; EMOTIONAL STRESS; ERYTHEMA; FAINTNESS; FEVER; FLUSHING; GRANULOCYTOSIS; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HOARSENESS; HUMAN; HYPERTENSION; HYPERVENTILATION; HYPOTENSION; HYPOXIA; LARYNX SPASM; LEUKOCYTOSIS; LEUKOPENIA; LYMPHOCYTOPENIA; MAST CELL; METALLIC TASTE; NANOMEDICINE; NONHUMAN; NOSE OBSTRUCTION; PANIC; PREMEDICATION; PRIORITY JOURNAL; PSEUDOALLERGY; RASH; RESPIRATORY DISTRESS; REVIEW; RHINITIS; RIGOR; SNEEZING; STRESS; STRIDOR; SWEATING; SWELLING; SYMPTOM; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; UNCONSCIOUSNESS; URTICARIA; VOMITING; WHEEZING;

ANIMALIA;

ALLERGY; ANAPHYLATOXINS; ANAPHYLAXIS; CARPA; INFLAMMATORY MEDIATORS; PSEUDOALLERGY;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; HYPERSENSITIVITY; NANOMEDICINE; STRESS, PHYSIOLOGICAL;

EID: 84907598811     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.06.038     Document Type: Review

References (81)

1. Adkinson N.F.J., Essayan D., Gruchalla R., Haggerty H., Kawabata T., Sandler J.D., Updyke L., Shear N.H., Wierda D., Force H.a.E.S.I.T. Task force report: future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions. J. Allergy Clin. Immunol. 2002, 109:S461-S478.
2. Alving C.R., Kinsky S.C., Haxby J.A., Kinsky C.B. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 1969, 8:1582-1587.
3. American National Standards Institute Biological evaluation of medical devices-Part 4: Selection of tests for interaction with blood. ANSI/AAMI/ISO 10993-4:2002/(R) March 2009.
4. Bradley A.J., Brooks D.E., Norris-Jonesa R., Devinea D.V. C1q Binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner. Biochim. Biphys. Acta 1999, 1418:19-30.
5. Brinks V., Jiskoot W., Schellekens H. Immunogenicity of therapeuticPproteins: the use of animal models. Pharm. Res. 2011, 28:2379-2385.
6. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., Muggia F.M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003, 14:1430-1437.
7. Chonn A., Cullis P.R., Devine D.V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 1991, 146:4234-4241.
8. Demoly P., Lebel B., Messaad D., Sahla H., Rongier M., Daures J.P., Godard P., Bousquet J. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy 1999, 54:500-506.
9. Descotes J., Choquet-Kastylevsky G. Gell and Coombs's classification: is it still valid?. Toxicology 2001, 158:43-49.
10. Dézsi L., Fülöp T., Mészáros T., Szénási G., Urbanics R., Vázsonyi C., Orfi E., Rosivall L., Nemes R., Jan Kok R., Metselaare J.M., Storm G., Szebeni J. Features of Complement Activation-Related Pseudoallergy to Liposomes with Different Surface Charge and PEGylation: comparison of the porcine and rat responses. J. Controlled Release 2014, In Press.
11. European Medicines Agency Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. EMA/CHMP/806058/2009/Rev. 02 February 2013.
12. Gabizon A.A., Muggia F.M. Initial Clinical Evaluation of Pegylated Liposomal Doxorubicin in Solid Tumors. Long-Circulating Liposomes: Old Drugs, New Therapeutics 1998, 155-174. Landes Bioscience, Austin, TX. M.C. Woodle, S.G. Austin (Eds.).
13. Garay R.P., El-Gewely R., Armstrong J.K., Garratty G., Richette P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Delivery 2012, 9:1319-1323.
14. Gell P.G.H., Coombs R.R.A. Classification of Allergic Reactions Underlying Disease 1963, Blackwell, Oxford.
15. Greenberger P.A. Contrast media reactions. J. Allergy. Clin. Immunol. 1984, 74:600-605.
16. Hamad I., Al-Hanbali O., Hunter A.C., Rutt K.J., Andresen T.L., Moghimi S.M. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 2010, 4:6629-6638.
17. Hamad I., Hunter A., Szebeni J., Moghimi S. Poly(ethylene glycol) s trigger complement activation in human serum through alternative and lectin pathways: a plausible cause for anaphylaxis. Mol. Immunol. 2008, 46(2):225-232.
18. Hamad I., Hunter A.C., Rutt K.J., Liu Z., Dai H., Moghimi S.M. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 2008, 45:3797-3803.
19. Hamad I., Hunter A.C., Szebeni J., Moghimi S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 2008, 46:225-232.
20. Hastings K.L. Implications of the new FDA/CDER immunotoxicology guidance for drugs. Int. Immunopharmacol. 2002, 11:1613-1618.
21. Hugli T.E. Structure and function of anaphylatoxins. Spring Semin. Immunopathol. 1984, 7:193-219.
22. Johansson S.G.O., Bieber T., Dahl R., Friedmann P.S., Lanier B.Q., Lockey R.F., Motala C., Ortega Martell J.A., Platts-Mills T., Ring J., Thien F.P.V.C., Williams H.C. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization. J. Allergy Clin. Immunol. 2003, 113:832-836.
23. Jun S.W., Kim T.H., Lee H.M., Lee S.H., Kim W.J., Park S.J., Kim Y.S., Lee S.H. Overexpression of the anaphylatoxin receptors, complement anaphylatoxin 3a receptor and complement anaphylatoxin 5a receptor, in the nasal mucosa of patients with mild and severe persistent allergic rhinitis. J. Allergy Clin. Immunol. 2008, 122:119-125.
24. Kinsky S.C., Haxby J.A., Zopf D.A., Alving C.R., Kinsky C.B. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry 1969, 8(10):4149-4158.
25. Kolb W.P., Lang J.H., Lasser E.C. Nonimmunologic complement activation in normal human serum induced by radiographic contrast media. J. Immunol. 1978, 1232-1238.
26. Lang J.H., Lasser E.C., Kolb W.P. Activation of serum complement by contrast media. Invest. Radiol. 1976, 303-308.
27. Lasser E.C., Lang J.H., Lyon S.G., Hamblin A.E. Complement and contrast material reactors. J. Allergy Clin. Immunol. 1979, 64:105-112.
28. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998, 279:1200-1205.
29. Lenz H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12:601-609.
30. Marceau F., Lundberg C., Hugli T.E. Effects of anaphylatoxins on circulation. Immunopharmacology 1987, 14:67-84.
31. McQuillan D. Introduction to Stress Theory 2008, http://wikieducator.org/Introduction_to_Stress_Theory.
32. Merk H., Goerz G. Analgetic drug intolerance. Z. Hautkr. 1983, 58:535-542.
33. Merkel O., Urbanics R., Bedocs P., Rozsnyay Z., Rosivall L., Toth M., Kissel T., Szebeni J. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials 2011, 32:4936-4942.
34. Meunier F., Prentice H.G., Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 1991, 28(Suppl. B):83-91.
35. Milosevits G., Rozsnyay Z., Kozma G.T., Milosevits J., Tömöry G., Robotka H., Rosivall L., Szebeni J. Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes. Chem. Phys. Lipids 2012, 165:482-487.
36. Moghimi S.M., Andersen A.J., Hashem S.H., Lettiero B., Ahmadvand D., Hunter A.C., Andresen T.L., Hamad I., Szebeni J. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J. Controlled Release 2010, 146:175-181.
37. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
38. Mousli M., Hugli T.E., Landry Y., Bronner C. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. J. Immunol. 1992, 148:2456-2461.
39. Muggia F., Hamilton A. Phase III data on Caelyx(R) in ovarian cancer. Eur. J. Cancer 2001, 37(Suppl. 9):15-18.
40. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997, 15:987-993.
41. Napolovlu K. The effect of epsilon-aminocaproic acid and prednisolone on the activation of the complement system due to x-ray contrast agents in rats in vitro. J. Eksp. Klin. Farmakol. 1997, 62-64.
42. Napolovlu K., Bolotova E.N., Shimanovskii N.L. The complement-activating action of modern x-ray contrast agents. J. Eksp. Klin. Farmakol. 1998, 61:60-64.
43. Niiya T., Litonius E., Peteja L., Neuvojen P.J. Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. Ann. Emergency Med. 2010, 56:402-408.
44. Pedersen M.B., Zhou X., Larsen E.K.U., Sorensen U.S., Kjems J., Nygaard J.V., Nyengaard J.R., Meyer R.L., Boesen T., Vorup-Jensen T. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 2010, 184:1931-1945.
45. Poirier V.J., Hershey A.E., Burgess K.E., Phillips B., Turek M.M., Forrest L.J., Beaver L., Vail D.M. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J. Vet. Intern. Med. 2004, 18:219-222.
46. Radford S.G., Lockyer J.A., Simpson P. Immunological aspects of adverse reactions to althesin. Br. J. Anaesth. 1982, 54:859-863.
47. Roerdink F., Wassef N.M., Richardson E.C., Alving C.R. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. Biochim. Biophys. Acta 1983, 734(1):33-39.
48. Schneider P., Klein R.M., Dietze L., Sohngen D., Leschke M., Heyll A. Anaphylactic reaction to liposomal amphotericin (AmBisome). Br. J. Haematol. 1998, 102:1108.
49. Selye J. Stress and disease. Science 1955, 122:625-631.
50. Senior J., Delgado C., Fisher D., Tilcock C., Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with polyethylene glycol coated vesicles. Biochim. Biophys. Acta 1991, 1062:77-82.
51. Skubitz K.M., Skubitz A.P. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil). Anticancer Drugs 1998, 9(1):45-50.
52. Szebeni J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 1998, 15(1):57-88.
53. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit. Rev. Ther. Drug Carrier Syst. 2001, 18:567-606.
54. Szebeni J. Hypersensitivity reactions to radiocontrast media: the role of complement activation. Curr. Allergy Asthma Rep. 2004, 4:25-30.
55. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur. J. Nanomed. 2012, 5:33-53.
56. Szebeni J., Alving C.R., Baranyi L., Bunger R. Interactions of liposomes with complement leading to adverse reactions. Liposome Technology Third Edition, Volume III: Interactions of Liposomes with the Biological Milieu 2007, 1-23. Informa Healthcare, New York/London. G. Gregoriadis (Ed.).
57. Szebeni J., Alving C.R., Muggia F.M. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Nat. Cancer Inst. 1998, 90(4):300-306.
58. Szebeni J., Alving C.R., Rosivall L., Bünger R., Baranyi L., Bedöcs P., Tóth M., Barenholz Y. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 2007, 17(2):107-117.
59. Szebeni J., Alving C.R., Savay S., Barenholz Y., Priev A., Danino D., Talmon Y. Formation of complement-activating particles in aqueous solutions of taxol: possible role in hypersensitivity reactions. Intern. Immunopharm. 2001, 1:721-735.
60. Szebeni J., Baranyi B., Savay S., Bodo M., Morse D.S., Basta M., Stahl G.L., Bunger R., Alving C.R. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 2000, 279:H1319-H1328.
61. ®). J. Liposome Res. 2000, 10:347-361.
62. Szebeni J., Baranyi L., Sávay S., Bodó M., Milosevits J., Alving C.R., Bünger R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. 2006, 290:H1050-H1058.
63. Szebeni J., Baranyi L., Savay S., Bodo M., Morse D.S., Basta M., Stahl G.L., Bünger R., Alving C.R. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 2000, 279(3):H1319-H1328.
64. Szebeni J., Baranyi L., Savay S., Milosevits J., Bodo M., Bunger R., Alving C.R. The interaction of liposomes with the complement system: in vitro and in vivo assays. Methods Enzymol. 2003, 373:136-154.
65. Szebeni J., Baranyi L., Savay S., Milosevits J., Bunger R., Laverman P., Metselaar J.M., Storm G., Chanan-Khan A., Liebes L., Muggia F.M., Cohen R., Barenholz Y., Alving C.R. Role of complement activation in hypersensitivity reactions to Doxil and HYNIC-PEG liposomes: experimental and clinical studies. J. Liposome Res. 2002, 12:165-172.
66. Szebeni J., Barenholz Y. Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes. Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications 2012, 309-334. Pan Standford Publishing Pte. Ltd., Singapore. D. Peer (Ed.).
67. Szebeni J., Bedocs P., Csukás D., Rosivall L., Bunger R., Urbanics R. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv. Drug Delivery Rev. 2012, 64:1706-1716.
68. Szebeni J., Bedocs P., Rozsnyay Z., Weiszhár Z., Urbanics R., Rosivall L., Cohen R., Garbuzenko O., Báthori G., Tóth M., Bünger R., Barenholz Y. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine NBM 2012, 8:176-184.
69. Szebeni J., Bedocs P., Urbanics R., Bunger R., Rosivall L., Tóth M., Barenholz Y. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J. Controlled Release 2012, 160:382-387.
70. Szebeni J., Fontana J.L., Wassef N.M., Mongan P.D., Morse D.S., Dobbins D.E., Stahl G.L., Bünger R., Alving C.R. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999, 99:2302-2309.
71. Szebeni J., Moghimi S.M. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions: biological recognition and interactions of liposomes. J. Liposome Res. 2009, 19(2):85-90.
72. Szebeni J., Muggia F., Gabizon G., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Delivery Rev. 2011, 63:1020-1030.
73. Szebeni J., Muggia F.M., Alving C.R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Nat. Cancer Inst. 1998, 90:300-306.
74. Szebeni J., Wassef N.M., Spielberg H., Rudolph A.S., Alving C.R. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem. Biophys. Res. Commun. 1994, 205:255-263.
75. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F.M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995, 13(7):1777-1785.
76. van den Hoven J.M., Nemes R., Metselaar J.M., Nuijen B., Beijnen J.H., Storm G., Szebeni J. Complement activation by PEGylated liposomes containing prednisolone. Eur. J. Pharm. Sci. 2013.
77. van der Kolk L.E., Grillo-López A.J., Baars J.W., Hack C.E., van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br. J. Haematol. 2001, 115:807-811.
78. Walsh T.J., Goodman J.L., Papas P., Bekersky I., Buell D.N., Roden M., Barrett J., Anaissie E.J. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 2001, 45:3487-3496.
79. Weiszhár Z., Czúcz J., Révész C., Rosivall L., Szebeni J., Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. 2012, 45:492-498.
80. Werfel T., Oppermann M., Butterfield J.H., Begemann G., Elsner J., Götze O., Zwirner J. The human mast cell line HMC-1 expresses C5a receptors and responds to C5a but not to C5a(desArg). Scand. J. Immunol. 1996, 44(1):30-36.
81. Wetsel R.A. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr. Opin. Immunol. 1995, 7:48-53.